TNBC: Potential Targeting of Multiple Receptors for a Therapeutic Breakthrough, Nanomedicine, and Immunotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Singh, D.D. | - |
dc.contributor.author | Yadav, D.K. | - |
dc.date.accessioned | 2021-09-04T01:40:35Z | - |
dc.date.available | 2021-09-04T01:40:35Z | - |
dc.date.created | 2021-08-11 | - |
dc.date.issued | 2021-08 | - |
dc.identifier.issn | 2227-9059 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/82037 | - |
dc.description.abstract | Triple-negative breast cancer (TNBC) is a heterogeneous, recurring cancer associated with a high rate of metastasis, poor prognosis, and lack of therapeutic targets. Although target-based therapeutic options are approved for other cancers, only limited therapeutic options are available for TNBC. Cell signaling and receptor-specific targets are reportedly effective in patients with TNBC under specific clinical conditions. However, most of these cancers are unresponsive, and there is a requirement for more effective treatment modalities. Further, there is a lack of effective biomarkers that can distinguish TNBC from other BC subtypes. ER, PR, and HER2 help identify TNBC and are widely used to identify patients who are most likely to respond to diverse therapeutic strategies. In this review, we discuss the possible treatment options for TNBC based on its inherent subtype receptors and pathways, such as p53 signaling, AKT signaling, cell cycle regulation, DNA damage, and programmed cell death, which play essential roles at multiple stages of TNBC development. We focus on poly-ADP ribose polymerase 1, androgen receptor, vascular endothelial growth factor receptor, and epidermal growth factor receptor as well as the application of nanomedicine and immunotherapy in TNBC and discuss their potential applications in drug development for TNBC. © 2021 by the authors. Licensee MDPI, Basel, Switzerland. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | MDPI | - |
dc.relation.isPartOf | Biomedicines | - |
dc.title | TNBC: Potential Targeting of Multiple Receptors for a Therapeutic Breakthrough, Nanomedicine, and Immunotherapy | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000688928600001 | - |
dc.identifier.doi | 10.3390/biomedicines9080876 | - |
dc.identifier.bibliographicCitation | Biomedicines, v.9, no.8 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85111708496 | - |
dc.citation.title | Biomedicines | - |
dc.citation.volume | 9 | - |
dc.citation.number | 8 | - |
dc.contributor.affiliatedAuthor | Yadav, D.K. | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Clinical trial | - |
dc.subject.keywordAuthor | Signaling pathway | - |
dc.subject.keywordAuthor | Therapeutic target | - |
dc.subject.keywordAuthor | Triple-negative breast cancer | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.